Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives

Código QR

Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives

Bobeck S Modjtahedi, 1–3 Tiffany Q Luong, 3 Stephan Chiu, 2 Tavé van Zyl, 4 Jane C Lin, 3 Donald S Fong 1–3 1Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park, CA, USA; 2Department of Ophthalmology, Southern California Permanente Medical Grou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Modjtahedi BS, Luong TQ, Chiu S, van Zyl T, Lin JC, Fong DS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	age-related macular degeneration glaucoma aqueous suppressant pharmacology pharmacokinetics vascular endothelial growth factor intravitreal injection Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/423b1006c9b4488aa681449d6287ba2f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi H, et al.
Publicado: (2018)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration
por: Wingard JB, et al.
Publicado: (2019)

Clinical Experience in the Administration of Intravitreal Injection Therapy at a Tertiary University Hospital in Jordan During the COVID-19 Lockdown
por: Saleh OA, et al.
Publicado: (2020)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
por: Solomon SD, et al.
Publicado: (2021)

Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections
por: Antaki F, et al.
Publicado: (2021)

Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation
por: Maruyama-Inoue M, et al.
Publicado: (2019)

Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
por: Arias L, et al.
Publicado: (2016)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

The Influence of Blue-Filtering Intraocular Lenses Implant on Exudative Age-Related Macular Degeneration: A Case–Control Study
por: Hamel T, et al.
Publicado: (2021)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema MR, et al.
Publicado: (2021)

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
por: Hall J
Publicado: (2016)

Dietary Antioxidants in Age-Related Macular Degeneration and Glaucoma
por: Jacek Dziedziak, et al.
Publicado: (2021)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
por: Kaya C, et al.
Publicado: (2019)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
por: Andrea Montesel, et al.
Publicado: (2021)

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy
por: Kinoshita T, et al.
Publicado: (2021)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017)

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
por: Sivaprasad S, et al.
Publicado: (2016)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
por: Xiu-Xian Wang, et al.
Publicado: (2021)

Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
por: Andrzej Grzybowski, et al.
Publicado: (2021)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Joseph Juliano, et al.
Publicado: (2021)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
por: Almeida DRP, et al.
Publicado: (2021)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)

Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study
por: Pece A, et al.
Publicado: (2016)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
por: Miyamoto N, et al.
Publicado: (2017)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa AC, et al.
Publicado: (2016)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki H, et al.
Publicado: (2017)

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review
por: Muste JC, et al.
Publicado: (2021)

Prefilled syringes for intravitreal drug delivery
por: Sassalos TM, et al.
Publicado: (2019)

Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor
por: Elfalah M, et al.
Publicado: (2021)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta H, et al.
Publicado: (2020)

Choriocapillaris Vascular Density Changes: Healthy vs. Advanced Exudative Age-Related Macular Degeneration Previously Treated with Multiple Anti-VEGF Intravitreal Injections
por: Maria Cristina Savastano, et al.
Publicado: (2021)

Implantation of the First IMT Macular Lens in Age-Related Macular Degeneration (Literature Review)
por: M. M. Bikbov, et al.
Publicado: (2019)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
por: Jing Wang, et al.
Publicado: (2021)

Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
por: Iannetta D, et al.
Publicado: (2021)